{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:54:24Z","timestamp":1762876464779,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bladder cancer (BC) presenting with pelvic and retroperitoneal lymph nodes presents a therapeutic challenge. The impact of chemoradiotherapy on pelvic and retroperitoneal lymph node metastasis as a consolidation treatment has not been established. Between 2009 and 2020, 502 patients who were treated with first-line chemotherapy for BC in our center, were retrospectively identified. Patients who received chemoradiotherapy or radiotherapy with an equivalent radiation dose superior to 30 Gy were included in the RTCT group, and other patients were included in the control group (CT group). We performed an analysis of progression-free survival (PFS) and overall survival (OS) for these two cohorts using the Kaplan\u2013Meier method. A total of 89 patients were included, 24 in the RTCT group and 65 in the CT group. Chemoradiotherapy improved both OS (p = 0.034) and PFS (p = 0.009) in comparison with chemotherapy alone: 26.3 months (95% IC 0.0\u201352.9) and 19.4 months (95% IC 5.0\u201333.7), respectively, in the RTCT group versus 17.2 months (95% IC 13.7\u201320.6) and 11.2 months (95% IC 8.6\u201313.8), respectively, in the CT group. Grade 3\/4 toxicity was related to chemotherapy and to chemoradiotherapy at levels of 31% and 24%, respectively. For mBC with metastatic regional or retroperitoneal lymph nodes, chemoradiotherapy seems to confer benefits for both OS and PFS.<\/jats:p>","DOI":"10.3390\/cancers15072069","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T01:37:02Z","timestamp":1680226622000},"page":"2069","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020"],"prefix":"10.3390","volume":"15","author":[{"given":"Alexandre","family":"Bertucci","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sainte Catherine Cancer Institute, 84918 Avignon, France"},{"name":"Medical Oncology Department, Institut Paoli-Calmettes, INSERM, CNRS, CRCM, Aix-Marseille University, 13005 Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lysian","family":"Cartier","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Sainte Catherine Cancer Institute, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Rollet","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sainte Catherine Cancer Institute, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Boustany","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sainte Catherine Cancer Institute, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Hilgers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sainte Catherine Cancer Institute, 84918 Avignon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.eururo.2019.06.032","article-title":"Incremental Utility of Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect","volume":"76","author":"Pederzoli","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and Cisplatin versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study","volume":"18","author":"Hansen","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/cncr.28477","article-title":"Double-Blind, Randomized, Phase 2 Trial of Maintenance Sunitinib versus Placebo after Response to Chemotherapy in Patients with Advanced Urothelial Carcinoma: Sunitinib in Urothelial Carcinoma","volume":"120","author":"Grivas","year":"2014","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1\/2\u2013Positive Metastatic Bladder Cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(17)30242-5","article-title":"Maintenance Therapy with Vinflunine plus Best Supportive Care versus Best Supportive Care Alone in Patients with Advanced Urothelial Carcinoma with a Response after First-Line Chemotherapy (MAJA.; SOGUG 2011\/02): A Multicentre, Randomised, Controlled, Open-Label, Phase 2 Trial","volume":"18","author":"Font","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2019.37.15_suppl.4503","article-title":"CALGB 90601 (Alliance): Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Gemcitabine and Cisplatin with Bevacizumab or Placebo in Patients with Metastatic Urothelial Carcinoma","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized Phase III Study Comparing Paclitaxel\/Cisplatin\/Gemcitabine and Gemcitabine\/Cisplatin in Patients with Locally Advanced or Metastatic Urothelial Cancer without Prior Systemic Therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1\/2 Open-Label Study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-Line Pembrolizumab in Cisplatin-Ineligible Patients with Locally Advanced and Unresectable or Metastatic Urothelial Cancer (KEYNOTE-052): A Multicentre, Single-Arm, Phase 2 Study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-Controlled Phase 3 Trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo after First-Line Chemotherapy in Patients with Metastatic Urothelial Cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","article-title":"Bladder Cancer: ESMO Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"25","author":"Bellmunt","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_17","first-page":"206","article-title":"Prognostic Impact of Local Radiotherapy on Metastatic Urothelial Carcinoma Patients Receiving Systemic Chemotherapy","volume":"50","author":"Abe","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","article-title":"Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score\u2013Weighted Analysis from the National Cancer Data Base","volume":"34","author":"Seisen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.clgc.2017.04.007","article-title":"Consolidative Radiotherapy in Metastatic Urothelial Cancer","volume":"15","author":"Shah","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1016\/j.ijrobp.2020.07.451","article-title":"Role of Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients without Progression and with No More Than Five Residual Metastatic Lesions Following First Line Systemic Therapy: A Retrospective Analysis","volume":"108","author":"Aboudaram","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clon.2020.07.008","article-title":"Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies","volume":"33","author":"Franzese","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non\u2013Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.clcc.2021.10.009","article-title":"Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer","volume":"21","author":"Lee","year":"2022","journal-title":"Clin. Color. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejca.2022.02.018","article-title":"Definition of Oligometastatic Esophagogastric Cancer and Impact of Local Oligometastasis-Directed Treatment: A Systematic Review and Meta-Analysis","volume":"166","author":"Kroese","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3109\/0284186X.2013.764010","article-title":"Androgen Deprivation and High-Dose Radiotherapy for Oligometastatic Prostate Cancer Patients with Less than Five Regional and\/or Distant Metastases","volume":"52","author":"Schick","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fonc.2012.00215","article-title":"Stereotactic Body Radiation Therapy in the Treatment of Oligometastatic Prostate Cancer","volume":"2","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The Biology and Treatment of Oligometastatic Cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and Classification of Oligometastatic Disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer Consensus Recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.semtcvs.2008.09.007","article-title":"Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer","volume":"20","author":"Price","year":"2008","journal-title":"Semin. Thorac. Cardiovasc. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2069\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:07:17Z","timestamp":1760123237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15072069"],"URL":"https:\/\/doi.org\/10.3390\/cancers15072069","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2023,3,30]]}}}